PMID- 21204737
OWN - NLM
STAT- MEDLINE
DCOM- 20120507
LR  - 20231105
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 10
IP  - 4
DP  - 2011 Jul
TI  - Initiating antiretrovirals during tuberculosis treatment: a drug safety review.
PG  - 559-74
LID - 10.1517/14740338.2011.546783 [doi]
AB  - INTRODUCTION: Integrating HIV and tuberculosis (TB) treatment can reduce 
      mortality substantially. Practical barriers to treatment integration still exist 
      and include safety concerns related to concomitant drug use because of drug 
      interactions and additive toxicities. Altered therapeutic concentrations may 
      influence the chances of treatment success or toxicity. AREAS COVERED: The 
      available data on drug-drug interactions between the rifamycin class of 
      anti-mycobacterials and the non-nucleoside reverse transcriptase inhibitor and 
      the protease inhibitor classes of antiretrovirals are discussed with 
      recommendations for integrated use. Additive drug toxicities, the impact of 
      immune reconstitution inflammatory syndrome (IRIS) and the latest data on 
      survival benefits of integrating treatment are elucidated. EXPERT OPINION: 
      Deferring treatment of HIV to avoid drug interactions with TB treatment or the 
      occurrence of IRIS is not necessary. In the integrated management of TB-HIV 
      co-infection, rational drug combinations aimed at reducing toxicities while 
      effecting TB cure and suppressing HIV viral load are possible.
FAU - Gengiah, Tanuja N
AU  - Gengiah TN
AD  - University of KwaZulu-Natal, Centre for the AIDS Programme of Research in South 
      Africa, 719 Umbilo Rd, Durban, 4013, South Africa. gengiaht1@ukzn.ac.za
FAU - Gray, Andrew L
AU  - Gray AL
FAU - Naidoo, Kogieleum
AU  - Naidoo K
FAU - Karim, Quarraisha Abdool
AU  - Karim QA
LA  - eng
GR  - D43TW00231/TW/FIC NIH HHS/United States
GR  - U19 AI051794-05/AI/NIAID NIH HHS/United States
GR  - D43 TW000231/TW/FIC NIH HHS/United States
GR  - AI51794/AI/NIAID NIH HHS/United States
GR  - U19 AI051794/AI/NIAID NIH HHS/United States
GR  - D43 TW000231-16/TW/FIC NIH HHS/United States
GR  - D43 TW000231-15/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20110105
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - Animals
MH  - Anti-Retroviral Agents/*administration & dosage/*adverse effects
MH  - Antitubercular Agents/*administration & dosage/*adverse effects
MH  - Drug Interactions/physiology
MH  - Drug-Related Side Effects and Adverse Reactions/chemically induced/metabolism
MH  - HIV Infections/drug therapy/metabolism
MH  - Humans
MH  - Treatment Outcome
MH  - Tuberculosis/*drug therapy/metabolism
PMC - PMC3114264
MID - NIHMS260345
EDAT- 2011/01/06 06:00
MHDA- 2012/05/09 06:00
CRDT- 2011/01/06 06:00
PHST- 2011/01/06 06:00 [entrez]
PHST- 2011/01/06 06:00 [pubmed]
PHST- 2012/05/09 06:00 [medline]
AID - 10.1517/14740338.2011.546783 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2011 Jul;10(4):559-74. doi: 10.1517/14740338.2011.546783. 
      Epub 2011 Jan 5.